Synthesis and Evaluation of Azole‐Substituted Tetrahydronaphthalenes as Inhibitors of P450 arom, P450 17, and P450 TxA2

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Archiv der Pharmazie

• Publication date

  1996-09-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/ardp.19963290506PMID 8779634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arimidex®: A potent and selective fourth-generation aromatase inhibitor

  2004cited by this paper
• Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17.

  1996cited by this paper
• Development of a screening assay for the in vitro evaluation of thromboxane A2 synthase inhibitors.

  1995cited by this paper
• Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom.

  1995cited by this paper
• Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins.

  1994cited by this paper
• Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha).

  1994cited by this paper
• Selective inhibition of steriodogenic P450 enzymes: current status and future perspectives

  1994cited by this paper
• Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds.

  1993cited by this paper
• Tissue-specific promoters regulate aromatase cytochrome P450 expression.

  1993cited by this paper
• Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.

  1993cited by this paper
• 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.

  1992cited by this paper
• Platelets and Cancer Metastasis: More Than an Epiphenomenon

  1992cited by this paper
• Evaluation of the racemate and the enantiomers of a new highly active and selective aromatase inhibitor of the aminoglutethimide type.

  1992cited by this paper
• Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives.

  1991cited by this paper
• Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.

  1991cited by this paper
• N-imidazolyl derivatives of the napththalene and chroman rings as thromboxane A2 synthase inhibitors

  1991cited by this paper
• New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives.

  1991cited by this paper
• Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal.

  1989cited by this paper
• Is there a case for P-450 inhibitors in cancer treatment?

  1989cited by this paper
• Increased synthesis of prostacyclin and thromboxane in human ovarian malignancy.

  1988cited by this paper
• Increased synthesis of prostacyclin and thromboxane in human ovarian malignancy.

  1988cited by this paper
• The Metastatic Cascade: Potential Approaches for the Inhibition of Metastasis

  1988cited by this paper
• Ketoconazole as a possible universal inhibitor of cytochrome P-450 dependent enzymes: its mode of inhibition.

  1987cited by this paper
• Inhibition of testicular 17α-hydroxylase and 17,20-lyase but not 3β-hydroxysteroid dehydrogenase-isomerase or 17β-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs

  1987cited by this paper
• Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs.

  1987cited by this paper
• N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.

  1986cited by this paper
• Synthesis of guanylhydrazones derived from 3-pyridinol and evaluation of their effect on serum thromboxane B2 and prostaglandin E2 production.

  1986cited by this paper
• Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme.

  1985cited by this paper
• Ketoconazole therapy in advanced prostatic cancer.

  1984cited by this paper
• Ketoconazole therapy in advanced prostatic cancer.

  1984cited by this paper
• Thromboxanes and prostacyclin: positive and negative modulators of tumor growth.

  1981cited by this paper
• Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives.

  1981cited by this paper
• The role of cytochrome P-450 in the action of sodium depletion on aldosterone biosynthesis in rats.

  1979cited by this paper
• Studies on the mechanism of estrogen biosynthesis in the rat ovary--I.

  1976cited by this paper
• A simple and precise assay of the enzymatic conversion of cholesterol into pregnenolone.

  1974cited by this paper
• Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione.

  1974cited by this paper
• Inhibition of prolactin by ergoline congeners.

  1974cited by this paper
• Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione.

  1974cited by this paper
• Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer.

  1962cited by this paper
• Synthetic Routes to 3,6-Dimethoxyphenanthrene

  1956cited by this paper
• REVIEWS

  1954cited by this paper
• A Simple Modification of the Wolff-Kishner Reduction

  1946cited by this paper
• Über Tetralinderivate mit basischer Seitenkette

  1937cited by this paper

• Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment

  2023cites this paper
• Phosphine Catalyzed Enantioselective Cascade Reaction Initiated by Intermolecular Cross Rauhut‐Currier Reaction of Electron‐Deficient ortho‐Formyl Styrenes

  2020cites this paper
• Human cytochrome P450 enzymes 5–51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition – toxic effects and benefits

  2018cites this paper
• New chroman-4-one/thiochroman-4-one derivatives as potential anticancer agents

  2017cites this paper
• Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.

  2017cites this paper
• 1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.

  2015cites this paper
• Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer

  2015cites this paper
• Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.

  2014cites this paper
• Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.

  2014cites this paper
• Design, synthesis and evaluation of novel 16-imidazolyl substituted steroidal derivatives possessing potent diversified pharmacological properties

  2012cites this paper
• Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.

  2012cites this paper
• 3-Pyridyl Substituted Aliphatic Cycles as CYP11B2 Inhibitors: Aromaticity Abolishment of the Core Significantly Increased Selectivity over CYP1A2

  2012cites this paper
• Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.

  2011cites this paper
• 17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.

  2011cites this paper
• Design, synthesis and antiproliferative activity of urocanic-chalcone hybrid derivatives

  2011cites this paper
• Non-steroidal CYP enzyme inhibitors as potential treatments for corticoid and estrogen related diseases

  2011cites this paper
• 17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.

  2011cites this paper
• CYP17 inhibition as a hormonal strategy for prostate cancer

  2008cites this paper
• CYP17 inhibitors for prostate cancer treatment--an update.

  2008cites this paper
• Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.

  2007cites this paper
• Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.

  2005cites this paper
• CYP 17 and CYP 19 Inhibitors. Evaluation of Fluorine Effects on the Inhibiting Activity of Regioselectively Fluorinated 1-(Naphthalen-2-ylmethyl)imidazoles

  2004cites this paper
• Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis.

  2003cites this paper
• Nonsteroidal aromatase inhibitors: Recent advances

  2002cites this paper
• Aromatase inhibitors

  2002cites this paper
• Novel steroidal vinyl fluorides as inhibitors of steroid C17(20) lyase.

  2002cites this paper
• 6-Substituted 3,4-Dihydro-naphthalene-2-carboxylic Acids: Synthesis and Structure-Activity Studies in a Novel Class of Human 5α Reductase Inhibitors

  2002cites this paper
• Inhibition of CYP 17, a New Strategy for the Treatment of Prostate Cancer

  2002cites this paper
• A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.

  2001cites this paper
• Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.

  2000cites this paper
• Novel imidazolyl and triazolyl substituted biphenyl compounds: synthesis and evaluation as nonsteroidal inhibitors of human 17alpha-hydroxylase-C17, 20-lyase (P450 17).

  2000cites this paper
• Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alpha-hydroxylase/C17-20-lyase (P450 17).

  2000cites this paper
• 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase.

  2000cites this paper
• Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.

  1999cites this paper
• MR 20492 and MR 20494: two indolizinone derivatives that strongly inhibit human aromatase.

  1999cites this paper
• Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer.

  1999cites this paper
• The biosynthesis of steroids and triterpenoids

  1998cites this paper
• Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.

  1998cites this paper
• Antitumor activity of new derivatives of 1,3-diazaheterocycles.

  1998cites this paper
• Synthesis of Novel Oximes of 2‐Aryl‐6‐methoxy‐3,4‐dihydronaphthalene and Their Evaluation as Inhibitors of 17α‐Hydroxylase‐C17,20‐Lyase (P450 17)

  1998cites this paper
• Metabolism of endobiotics and therapeutic aspects of P450 inhibitors

  1997cites this paper
• Synthesis of Z- and E-1-methyl-2-(1-hydroximinoethyl)-6-methoxy-3,4-dihydronaphthalene and evaluation as inhibitors of 17 alpha-hydroxylase-C17,20-lyase (P450 17).

  1997cites this paper
• Synthesis of Z‐ and E‐1‐Methyl‐2‐(1‐hydroximinoethyl)‐6‐methoxy‐3,4‐dihydronaphthalene and Evaluation as Inhibitors of 17α‐Hydroxylase‐C17,20‐Lyase (P450 17)

  1997cites this paper
• Novel Highly Active Thromboxane A2 Synthase Inhibitors Devoid of Carboxylic Groups

  1997cites this paper